Is Cns Pharmaceuticals Stock a Good Investment?
Cns Pharmaceuticals Investment Advice | CNSP |
- Examine Cns Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Cns Pharmaceuticals' leadership team and their track record. Good management can help Cns Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Cns Pharmaceuticals' business and its evolving consumer preferences.
- Compare Cns Pharmaceuticals' performance and market position to its competitors. Analyze how Cns Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Cns Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Cns Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Cns Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Cns Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves totally opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Cns Pharmaceuticals Stock
Researching Cns Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book (P/B) ratio of 1.71. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cns Pharmaceuticals recorded a loss per share of 352.97. The entity had not issued any dividends in recent years. The firm had 1:50 split on the 5th of June 2024.
To determine if Cns Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cns Pharmaceuticals' research are outlined below:
Cns Pharmaceuticals generated a negative expected return over the last 90 days | |
Cns Pharmaceuticals has high historical volatility and very poor performance | |
Cns Pharmaceuticals has some characteristics of a very speculative penny stock | |
Cns Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
Net Loss for the year was (18.85 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Cns Pharmaceuticals currently holds about 8.96 M in cash with (14.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Cns Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
Latest headline from news.google.com: CNS Pharmaceuticals Advances Berubicin and TPI 287 Projects - MSN |
Cns Pharmaceuticals Quarterly Good Will |
|
Cns Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cns Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cns Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
1st of April 2024 Upcoming Quarterly Report | View | |
31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact Cns Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Cns Pharmaceuticals' investors have experienced.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-11-13 | 2024-09-30 | -0.1 | -0.2527 | -0.1527 | 152 | ||
2023-11-13 | 2023-09-30 | -2.4 | -2.7 | -0.3 | 12 | ||
2022-11-10 | 2022-09-30 | -2.4 | -2.7 | -0.3 | 12 | ||
2022-08-12 | 2022-06-30 | -2.4 | -2.7 | -0.3 | 12 | ||
2021-08-13 | 2021-06-30 | -3.9 | -4.5 | -0.6 | 15 | ||
2020-05-15 | 2020-03-31 | -3 | -3.6 | -0.6 | 20 | ||
2019-12-20 | 2019-09-30 | -0.9 | -1.5 | -0.6 | 66 | ||
2021-11-12 | 2021-09-30 | -4.87 | -4.2 | 0.67 | 13 |
Know Cns Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cns Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cns Pharmaceuticals backward and forwards among themselves. Cns Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Cns Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Parallel Advisors, Llc | 2024-09-30 | 0.0 | Smith Anglin Financial, Llc | 2024-06-30 | 0.0 | Fmr Inc | 2024-09-30 | 0.0 | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 0.0 | Vanguard Group Inc | 2024-06-30 | 0.0 | Anson Funds Management Lp | 2024-09-30 | 0.0 | Fsm Wealth Advisors, Llc | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-06-30 | 0.0 | Xtx Topco Ltd | 2024-06-30 | 0.0 | Geode Capital Management, Llc | 2024-09-30 | 203.2 K | Ubs Group Ag | 2024-09-30 | 181.9 K |
Cns Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.28 M.Market Cap |
|
Cns Pharmaceuticals' profitablity analysis
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (12.75) | (12.11) | |
Return On Capital Employed | 4.89 | 5.14 | |
Return On Assets | (12.75) | (12.11) | |
Return On Equity | 4.89 | 3.37 |
Determining Cns Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Cns Pharmaceuticals is a good buy. For example, gross profit margin measures Cns Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cns Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Cns Pharmaceuticals' management efficiency
Cns Pharmaceuticals has return on total asset (ROA) of (2.24) % which means that it has lost $2.24 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.1878) %, meaning that it created substantial loss on money invested by shareholders. Cns Pharmaceuticals' management efficiency ratios could be used to measure how well Cns Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/01/2025, Return On Capital Employed is likely to grow to 5.14, though Return On Tangible Assets are likely to grow to (12.11). As of 02/01/2025, Total Current Liabilities is likely to grow to about 7.4 M, while Liabilities And Stockholders Equity is likely to drop slightly above 1.9 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | (67.96) | (64.56) | |
Tangible Book Value Per Share | (67.96) | (64.56) | |
Enterprise Value Over EBITDA | (0.22) | (0.23) | |
Price Book Value Ratio | (0.97) | (1.02) | |
Enterprise Value Multiple | (0.22) | (0.23) | |
Price Fair Value | (0.97) | (1.02) |
Leadership at Cns Pharmaceuticals emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Beta 1.049 |
Basic technical analysis of Cns Stock
As of the 1st of February, Cns Pharmaceuticals shows the Mean Deviation of 4.37, standard deviation of 6.37, and Risk Adjusted Performance of (0.05). Cns Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Cns Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cns Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cns Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cns Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cns Pharmaceuticals' Outstanding Corporate Bonds
Cns Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cns Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cns bonds can be classified according to their maturity, which is the date when Cns Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
CNO 175 07 OCT 26 Corp BondUS18977W2A75 | View | |
CNO 265 06 JAN 29 Corp BondUS18977W2C32 | View | |
COACH INC 425 Corp BondUS189754AA23 | View | |
US189754AC88 Corp BondUS189754AC88 | View | |
NOVHOL 6625 15 APR 29 Corp BondUS18972EAA38 | View |
Understand Cns Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Cns Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
Risk Adjusted Performance | (0.05) | |||
Market Risk Adjusted Performance | 0.3893 | |||
Mean Deviation | 4.37 | |||
Coefficient Of Variation | (1,534) | |||
Standard Deviation | 6.37 | |||
Variance | 40.55 | |||
Information Ratio | (0.08) | |||
Jensen Alpha | (0.32) | |||
Total Risk Alpha | (1.11) | |||
Treynor Ratio | 0.3793 | |||
Maximum Drawdown | 24.15 | |||
Value At Risk | (9.09) | |||
Potential Upside | 10.0 | |||
Skewness | 0.1083 | |||
Kurtosis | (0.21) |
Risk Adjusted Performance | (0.05) | |||
Market Risk Adjusted Performance | 0.3893 | |||
Mean Deviation | 4.37 | |||
Coefficient Of Variation | (1,534) | |||
Standard Deviation | 6.37 | |||
Variance | 40.55 | |||
Information Ratio | (0.08) | |||
Jensen Alpha | (0.32) | |||
Total Risk Alpha | (1.11) | |||
Treynor Ratio | 0.3793 | |||
Maximum Drawdown | 24.15 | |||
Value At Risk | (9.09) | |||
Potential Upside | 10.0 | |||
Skewness | 0.1083 | |||
Kurtosis | (0.21) |
Consider Cns Pharmaceuticals' intraday indicators
Cns Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cns Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 291686.0 | |||
Daily Balance Of Power | (0.67) | |||
Rate Of Daily Change | 0.97 | |||
Day Median Price | 0.0976 | |||
Day Typical Price | 0.0973 | |||
Price Action Indicator | (0) | |||
Period Momentum Indicator | (0) |
Cns Stock media impact
Far too much social signal, news, headlines, and media speculation about Cns Pharmaceuticals that are available to investors today. That information is available publicly through Cns media outlets and privately through word of mouth or via Cns internal channels. However, regardless of the origin, that massive amount of Cns data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cns Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cns Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cns Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cns Pharmaceuticals alpha.
Additional Tools for Cns Stock Analysis
When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.